HIMS: What's The ER Can Bring About?

Hello everyone! Today i want to share some trading ideas with you!

Here are my thoughts on the $Hims & Hers Health Inc.(HIMS)$ earnings 🧐

Hims & Hers Health has effectively capitalized on a unique market opportunity amid a shortage of FDA-approved GLP-1 drugs. The company introduced a compounded version of Novo Nordisk's popular weight loss medication, priced at $79 per month for oral intake and $199 for injections -- this strategic move is part of Hims's larger goal to boost its weight loss product line to $100M in sales by 2025.

Hims reported their Q2 2024 earnings this week with revenues of $316M, a 52% YoY increase -- surpassing the $295M guidance. The company increased its subscriber base to 1.9M, up 43% YoY. This impressive performance suggests that the impact of GLP-1 compounded drugs has exceeded expectations -- contributing to growth alongside Hims's broader product offerings.

Excluding GLP-1s, Hims still achieved a 46% growth in Q2 2024, reflecting robust expansion. The company's weight loss program, excluding GLP-1s, generated $100M in just 6 months, marking the fastest new product growth in the company's history. Hims has successfully marketed products like branded Viagra, generic Viagra, and customized compounds, and anticipates similar success with the integration of GLP-1s into its legacy weight loss program.

Looking ahead, Hims plans to expand its influence in the health and wellness market with a focus on personalized health solutions, using AI and data analytics to develop targeted treatments. The planned transition from temporary compounded drugs to permanent, FDA-approved GLP-1 treatments is expected to bolster customer retention and satisfaction.

Hims continues to diversify and strengthen its product offerings beyond temporary solutions. The company’s existing portfolio includes telehealth services, prescription skincare products, and mental health solutions, all tailored to meet the specific needs of its users. These core offerings, combined with recent expansions into weight loss treatments, position Hims to not only meet immediate consumer demands but also to build a sustainable, comprehensive health and wellness platform.

Follow me to learn more about analysis!!

https://x.com/StockSavvyShay/status/1821168725929947366

Q2 Earnings: What Opportunities to Focus Amid Pullback?

This week, the Q2 earnings season will see a very busy week. Tech giants including Microsoft, Meta, Apple and Amazon, semiconductor stocks like AMD, ARM and QCOM, and crypto stocks Coinbase, Microstrategy will release earnings. ------------------ Do you think this earnings season will repeat April's pattern or not? What other chances to focus as the tech stocks pullback?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

HIMS: What's The ER Can Bring About?

Comments